Literature DB >> 1567169

Monoclonal antibody 83D4 immunoreactivity in human tissues: cellular distribution and microcytophotometric analysis of immunoprecipitates on tissue sections.

C Charpin1, G Pancino, E Osinaga, P Bonnier, M N Lavaut, C Allasia, A Roseto.   

Abstract

Immunocytochemical assays were performed on cell cultures as well as on a wide range of human tissues using a monoclonal antibody, MAb 83D4, produced by a murine hybridoma generated by immunization with a cell suspension from a paraffin block of human breast carcinoma tissue. Frozen breast tissue samples (n = 49) were compared to fixed and paraffin-embedded samples (n = 62). Paraffin sections (n = 194) from a variety of human tissues were compared to breast immunoreactivity. Immunoprecipitates, resulting from positive reactions between 83D4 and Avidin Biotin Peroxidase, were evaluated by computer-assisted microcytophotometry (SAMBA). In some frozen breast samples (n = 27), 83D4 antigen distribution was correlated with tumor cell DNA index, ploidy balance, growth fraction (Ki67), hormone receptor (ER, PR) antigenic sites, NORsAg and oncoprotein pHER-2/neu cell content. MAb 83D4 reacted with 3 breast cancer cells lines (MCF7, T47D and H466B) but not with normal epithelial breast cells in culture. The immunostaining in frozen paraffin sections from breast were similar. Like most normal tissues, normal breast did not react with 83D4. Cellular MAb 83D4 antigen concentration increases with the degree of malignancy but is independent of DNA nuclear content, ER, PR, growth fraction and pHER-2neu in cancers. These results suggested that routine immunohistochemical procedures using MAb 83D4 could facilitate the grading of breast cancer, in particular by allowing detection of microvascular invasions in the breast as well as at a distance and of blood-born micrometastases, especially in bone marrow.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1567169

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Resolving conflicting data on expression of the Tn antigen and implications for clinical trials with cancer vaccines.

Authors:  Qian Li; Miriam R Anver; Donna O Butcher; Jeffrey C Gildersleeve
Journal:  Mol Cancer Ther       Date:  2009-04       Impact factor: 6.261

2.  Immunocytological analysis of the Tn associated antigen 83D4 in serous effusions from patients with cancer: comparison with Tn soluble glycoprotein.

Authors:  M Beuzelin-Yvraut; A Bourguignat; E Phillips; A Roseto; E Osinaga
Journal:  J Clin Pathol       Date:  1995-05       Impact factor: 3.411

3.  Effective antitumor therapy based on a novel antibody-drug conjugate targeting the Tn carbohydrate antigen.

Authors:  Christine Sedlik; Adèle Heitzmann; Sophie Viel; Rafik Ait Sarkouh; Cornélie Batisse; Frédéric Schmidt; Philippe De La Rochere; Nathalie Amzallag; Eduardo Osinaga; Pablo Oppezzo; Otto Pritsch; Xavier Sastre-Garau; Pascale Hubert; Sebastian Amigorena; Eliane Piaggio
Journal:  Oncoimmunology       Date:  2016-04-22       Impact factor: 8.110

4.  Analysis of a heterogeneous group of human breast carcinoma associated glycoproteins bearing the Tn determinant.

Authors:  E Osinaga; G Pancino; N Porchet; N Berois; P De Cremoux; D Mistro; J P Aubert; F Calvo; A Roseto
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

5.  Re-HEDP : pharmacokinetic characterization, clinical and dosimetric evaluation in osseous metastatic patients with two levels of radiopharmaceutical dose.

Authors:  Eduardo Savio; Javier Gaudiano; Ana M Robles; Henia Balter; Andrea Paolino; Andrea López; Juan C Hermida; Eugenia De Marco; Graciela Martinez; Eduardo Osinaga; Furn F Knapp
Journal:  BMC Nucl Med       Date:  2001

6.  Onco-Golgi: Is Fragmentation a Gate to Cancer Progression?

Authors:  Armen Petrosyan
Journal:  Biochem Mol Biol J       Date:  2015-11-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.